Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Axatilimab at 3 Different Doses in Patients With Chronic Graft Versus Host Disease (cGVHD)

Hematologic

AGAVE-201 is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in patients with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy due to progression of disease, intolerability or toxicity.
Hematologic
II
Kitko, Carrie
NCT04710576
VICCCTT20119

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: